# US 2014/0005144 A1 · Novel leukotriene receptor antagonist

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0005144 A1
- Document ID: US20140005144A1
- Status: Published application
- Kind: A1
- Application number: 14/012,023
- Filed: 2013-08-28
- Published: 2014-01-02
- Earliest claimed: 2007-05-11
- Assignees: Bizen Chemical Co., Ltd.
- Applicants: Bizen Chemical Co., Ltd.
- Inventors: Teruyuki Kanada; Toru Kuyama; Takahiko Hada; Takafumi Ishihara
- Web page: https://patentgrep.com/patent/US20140005144A1

## CPC

- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A23L 2/52: Adding ingredients (adding preservatives A23B70/10)
- A23L 17/40: Shell-fish
- A23L 17/50: Molluscs
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 31/66: Phosphorus compounds
- A61K 31/683: Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K 35/612: Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
- A61K 35/618: Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

It is an object of the present invention to provide a leukotriene receptor antagonist that can be conveniently prepared from a natural source. The object has been achieved by finding that a marine product such as a squid phospholipid extract or an Akiami paste shrimp phospholipid extract contains the antagonists of BLT and CysLT1, which are leukotriene receptors. Therefore, the present invention provides a dietary composition and a pharmaceutical composition for inhibiting the activity of leukotriene receptors, containing a squid phospholipid extract or an Akiami paste shrimp phospholipid extract.

## Claims

### Claim 1

A method for inhibiting the activity of a leukotriene receptor, comprising a step of administering a phospholipid extract of a marine product.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the marine product is selected from the group consisting of squid, krill and Akiami paste shrimp.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the phospholipid extract of a marine product is an ethanol extract.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the leukotriene receptor is a BLT receptor.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the leukotriene receptor is a CysLT1 receptor.

### Claim 6

A method for the prevention and/or treatment of a disease selected from the group consisting of ulcerative colitis, interstitial pneumonia, atopic dermatitis, contact-type dermatitis, psoriasis, bronchial asthma, chronic obstructive pulmonary diseases, sporadic lethal asthma and ischemic renal diseases, wherein the method comprises a step of administering a phospholipid extract of a marine product having a BLT receptor inhibitory activity.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the marine product is selected from the group consisting of squid, krill and Akiami paste shrimp.

### Claim 8

A method for the prevention and/or treatment of a disease selected from the group consisting of bronchial asthma, bronchiolitis, allergic rhinitis, atopic dermatitis, mastocytoma and ischemic cardiac diseases, wherein the method comprises a step of administering a phospholipid extract of a marine product having a CysLT1 receptor inhibitory activity.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the marine product is selected from the group consisting of squid, krill and Akiami paste shrimp.
